A Clinical Study Evaluating Inhaled Aviptadil on COVID-19
- Registration Number
- NCT04844580
- Lead Sponsor
- Centurion Pharma
- Brief Summary
This study is a multicenter, prospective, placebo-controlled, comparative, randomized, double-blind local phase II clinical trial. Duration of study is 18 months. In the study, patients will be randomized in a ratio of 1: 1 into two arms, standard medical therapy + placebo versus standard medical therapy + inhaled Aviptadil arms. Randomization will be carried out by the block randomization method. In the event that patients need intensive care in the study, the patients will be taken into intensive care unit and excluded from the study and their treatment will be continued in the intensive care unit as deemed appropriate by the physician and it is foreseen that inhaled Aviptadil will be used for a period of minimum 7 and maximum 14 days. Aviptadil will be discontinued in patients who do not heal after 14 days. This study includes 8 visits, consisting of a total of 7 physical visits and 1 phone follow-up visit. The study period will be 6 months for each patient. Patient recruitment is planned to take 12 months. Study centers will be asked to use investigational products for their patients who sign the informed consent form for 12 months. The study population will consist of patients 18 years of age and older with COVID-19 pulmonary involvement and hospitalized patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 80
1.18 years and older women or men, under 70 years old
2.Patients with positive SARS-CoV-2 real time PCR result and an appearance in line with COVID-19 pneumonia on thorax CT
-
Need for oxygen support or SpO2 <94 in room air
-
Patients who can use a nebulizer (with assistance when necessary)
5.Patients who are willing and capable (mentally and physically) who can sign a written informed consent form, to participate in all aspects of the study, to participate in the planned visits and to comply with the terms of the protocol.
-
Intensive care admission
-
The need for mechanical ventilation
-
Patients with previously known organ (kidney, heart and liver) failure
* To be determined as previously known heart failure (EF <30), previously known liver failure (Child-Pugh C) and previously known renal failure (Cr.clerance <30).
-
COVID-19 disease with no indication for hospitalization
-
Participants in another clinical trial
-
Pregnancy or lactation
-
Solid organ or stem cell transplantation story
-
Patients with collagen tissue disease
-
Use of immunosuppressive therapy
-
Procalcitonin ≥2 (baseline visit)
-
Under 18 years old
-
Those who had myocardial infarction in the last 3 months
-
Those who do not have the capacity to understand the possible results, scope and nature of the study due to legal insufficiency and / or other reasons.
-
Those who, in the opinion of the investigator, cannot continue the treatment protocol regularly or cannot cooperate
-
Presence of malignancy
-
Patients with neurological diseases
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Standard Treatment + Placebo Placebo Standard medical treatment, as deemed appropriate by physicians, is going to be according to the Turkish Republic COVID-19 (SARS-CoV-2 INFECTION) ADULT PATIENT TREATMENT GUIDELINES published by the Ministry of Health, General Directorate of Public Health. The management of all additional complications and / or symptoms that develop in patients will be managed in the same way as specified in these guidelines. If these guidelines are changed by the Turkish Republic Ministry of Health General Directorate of Public Health, a protocol amendment will be planned. The necessary changes within the scope of urgent security measures will be reflected in the standard treatment in accordance with the necessary regulations. Standard Treatment + Inhaled Aviptadil Inhaled Aviptadil In addition to the standard medical treatment mentioned above, patients randomized to this arm will be given Inhaled Aviptadil 2 times a day, 30 minutes apart. Aviptadil treatment is aimed to be a minimum of 7 days and a maximum of 14 days. Aviptadil will be discontinued in patients who do not heal after 14 days. The dose of inhaled Aviptadil was determined by evaluating the results of the Phase 1 and Phase 2 studies.
- Primary Outcome Measures
Name Time Method Clinical improvement 6 months Being discharged within 30 days of starting treatment, no need for oxygen support
- Secondary Outcome Measures
Name Time Method The rate of patients entering intensive care 6 months Patients' rate of needing mechanical ventilation 6 months Normalization in body temperature 14 days Normalization in Respiration Rate/Minute 14 days Time to discharge of patients 6 months Change in SpO2 (measured by pulse oximetry) 6 months The time it takes for the PCR to become negative 14 days Sequelae and recovery rates in control thorax computed tomography at the end of month 1 and 6 months 6 months Need for re-hospitalization 6 months Normalization in laboratory results of blood parameters (PT, aPTT, D-dimer, Ferritin, Lymphocyte Count, CRP) 28 days Normalization in laboratory results of biochemistry parameters (Glucose, ALT, AST, LDH, Total Bilirubin, Total Protein, Albumin, Alkaline Phosphatase, GGT, Sodium, Potassium, Calcium, Phosphor, CPK, Magnesium, eGFR, BUN, Uric Acid, Creatinine Clearance) 28 days Mortality rate 6 months Normalization in Blood Pressure 14 days Dyspnea Scale (Modified Borg Dyspnea Scale (MBS) 6 months 6-minute walking test 28 days The time it takes for patients to improvement of their symptoms (cough, shortness of breath) 6 months Normalization in SpO2 14 days
Trial Locations
- Locations (9)
Kocaeli Üniversitesi Tıp Fakültesi Hastanesi
🇹🇷Kocaeli, Turkey
Başkent University School of Medicine
🇹🇷Ankara, Turkey
Prof. Dr. Murat Dilmener Acil Durum Hastanesi
🇹🇷Istanbul, Turkey
Prof. Dr. Feriha Öz Acil Durum Hastanesi
🇹🇷Istanbul, Turkey
Dicle Üniversitesi Tıp Fakültesi Hastanesi
🇹🇷Diyarbakır, Turkey
Hacettepe University School of Medicine
🇹🇷Ankara, Turkey
Başakşehir Çam ve Sakura Şehir Hastanesi
🇹🇷Istanbul, Turkey
Health Sciences University Yedikule Training and Research Hospital
🇹🇷Istanbul, Turkey
Karadeniz Teknik Üniversitesi Tıp Fakültesi Hastanesi
🇹🇷Trabzon, Turkey